Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

3.34USD
19 Oct 2018
Change (% chg)

$-0.09 (-2.62%)
Prev Close
$3.43
Open
$3.43
Day's High
$3.49
Day's Low
$3.34
Volume
165,655
Avg. Vol
239,415
52-wk High
$3.93
52-wk Low
$1.59

Latest Key Developments (Source: Significant Developments)

Antares Pharma Q4 Loss Per Share $0.02
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.02.Q4 EARNINGS PER SHARE VIEW $-0.03 -- THOMSON REUTERS I/B/E/S.ANTARES PHARMA - QTRLY TOTAL REVENUE $14.0 MILLION VERSUS $14.2 MILLION.  Full Article

AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector
Wednesday, 14 Feb 2018 06:03pm EST 

Feb 14 (Reuters) - Amag Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN.AMAG PHARMACEUTICALS - EXPECTS TO FILE A NEW DRUG APPLICATION THIS QUARTER FOR A NEW CHEMICAL ENTITY (BREMELANOTIDE) ​.AMAG PHARMACEUTICALS INC - ‍EXPECTS SUBCUTANEOUS AUTO-INJECTOR TO BE AVAILABLE IN SECOND HALF OF MARCH​.AMAG PHARMACEUTICALS INC - WILL CONTINUE TO OFFER IM FORMULATION OF MAKENA IN BOTH SINGLE-DOSE AND MULTI-DOSE VIALS​.AMAG PHARMACEUTICALS INC - ‍MAKEN'S 7-YEAR ORPHAN DRUG EXCLUSIVITY EXPIRED EARLIER THIS MONTH​.AMAG PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF MAKENA (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR ‍​.  Full Article

Antares Pharma Provides Xyosted Regulatory Update
Tuesday, 16 Jan 2018 07:00am EST 

Jan 16 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE.ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED.ANTARES PHARMA - REQUEST FOR MEETING WAS IN RESPONSE TO COMPLETE RESPONSE LETTER RECEIVED BY ANTARES REGARDING NEW DRUG APPLICATION FOR XYOSTED.  Full Article

Antares Pharma Q3 loss per share $0.03
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Antares Pharma Inc :Antares Pharma reports third quarter 2017 operating and financial results.Q3 loss per share $0.03.Q3 revenue $15.1 million versus I/B/E/S view $14 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Antares Pharma - ‍at September 30, 2017, cash, cash equivalents and short-term investments were $37.4 million compared to $27.7 million at December 31, 2016​.  Full Article

Antares Pharma receives complete response letter from FDA for Xyosted
Friday, 20 Oct 2017 06:48pm EDT 

Oct 20 (Reuters) - Antares Pharma Inc :Antares pharma receives complete response letter from the fda for Xyosted.‍CRL indicates that FDA cannot approve NDA in its present form​.‍FDA is concerned that Xyosted could cause a clinically meaningful increase in blood pressure​.‍CRL identified two deficiencies related to clinical data for Xyosted injection​.Complete response ‍letter also raised a concern regarding occurrence of depression and suicidality​.  Full Article

Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted
Thursday, 12 Oct 2017 05:00pm EDT 

Oct 12 (Reuters) - Antares Pharma Inc :Antares Pharma provides Xyosted™ regulatory update.Antares Pharma Inc - ‍anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017​.Antares Pharma Inc - ‍intends to work with FDA to understand nature of deficiencies once identified.Antares Pharma Inc - ‍received a letter from FDA regarding Xyosted .Antares Pharma Inc - ‍ letter from U.S. FDA does not specify deficiencies identified with respect to review of Xyosted NDA​.Antares Pharma Inc - got letter on Oct 11 stating FDA identified deficiencies precluding continuation of discussion of labeling, postmarketing needs at this time​.  Full Article

Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals
Tuesday, 10 Oct 2017 07:00am EDT 

Oct 10 (Reuters) - Antares Pharma Inc ::Antares Pharma announces sale of Zomajet™ needle-free delivery system to Ferring Pharmaceuticals.Antares Pharma Inc - deal for ‍up to $14.5 million​.Antares - to sell worldwide rights, including certain fixed assets, for Zomajet needle-free auto injector device to Ferring Pharmaceuticals​.Antares - deal with Ferring generates non-dilutive cash which co intends to use to invest to support launch of Xyosted​.  Full Article

Antares Pharma Q2 loss per share $0.02
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Antares Pharma Inc ::Antares pharma reports second quarter 2017 operating and financial results.Q2 loss per share $0.02.Q2 revenue $13.4 million versus I/B/E/S view $12.5 million.Q2 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma files $200 mln mixed shelf
Tuesday, 9 May 2017 05:03pm EDT 

May 9 (Reuters) - Antares Pharma Inc :Files for mixed shelf of up to $200 million - sec filing.  Full Article

Antares Pharma reports Q1 loss per share $0.03
Tuesday, 9 May 2017 07:00am EDT 

May 9 (Reuters) - Antares Pharma Inc : :Antares Pharma reports first quarter 2017 operating and financial results.Q1 revenue $12 million versus I/B/E/S view $12.3 million.Q1 loss per share $0.03.Q1 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.  Full Article

Antares Pharma's testosterone drug gets FDA approval

The U.S. Food and Drug Administration on Monday approved Antares Pharma Inc's injectable drug to treat low testosterone levels in men, the company said, nearly a year after being rejected.

No consensus analysis data available.